Welcome to LookChem.com Sign In|Join Free

CAS

  • or

223673-35-6

Post Buying Request

223673-35-6 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • (N-tert-Butoxycarbonyl-N-[(1’R)-hydroxy-1-phenyl)ethyl])-4-nitrophenylethylamine

    Cas No: 223673-35-6

  • No Data

  • No Data

  • No Data

  • BOC Sciences
  • Contact Supplier

223673-35-6 Usage

Chemical Properties

Yellow Semi-Solid

Uses

Mirabegron intermediate.

Check Digit Verification of cas no

The CAS Registry Mumber 223673-35-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 2,2,3,6,7 and 3 respectively; the second part has 2 digits, 3 and 5 respectively.
Calculate Digit Verification of CAS Registry Number 223673-35:
(8*2)+(7*2)+(6*3)+(5*6)+(4*7)+(3*3)+(2*3)+(1*5)=126
126 % 10 = 6
So 223673-35-6 is a valid CAS Registry Number.

223673-35-6SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 19, 2017

Revision Date: Aug 19, 2017

1.Identification

1.1 GHS Product identifier

Product name (N-tert-Butoxycarbonyl-N-[(1,R)-hydroxy-1-phenyl)ethyl])-4-nitrophenylethylamine

1.2 Other means of identification

Product number -
Other names tert-butyl N-[(2R)-2-hydroxy-2-phenylethyl]-N-[2-(4-nitrophenyl)ethyl]carbamate

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:223673-35-6 SDS

223673-35-6Downstream Products

223673-35-6Relevant articles and documents

Systematic Investigation into the Formation of Significant Amounts of Unknown Impurity during Scale-up of NaBH4-I2 Mediated Reduction of Nitro-Amide Intermediate of Mirabegron No.

Bangal, Mukund N.,Deshmukh, Dattatray G.,Kalawade, Kaustubh A.,Mathad, Vijayavitthal T.

, p. 286 - 293 (2020)

After successful development of a manufacturing process for the Mirabegron (1) at the laboratory scale, a muddled situation was aroused during the scale-up batches, wherein sodium borohydride-iodine (NaBH4-I2) mediated reduction of nitro-amide 4 ended up with substantial amounts (~10%) of unspecified impurity in the nitro-amine intermediate 5. On the basis of the structure elucidation and meticulous investigation, a reaction path for its genesis during the process was identified and an efficient mechanism proposed to arrest its formation. In-situ generated nickel boride (Ni2B) due to reaction of NiI2 (corrosion product) with NaBH4 followed by electrophilic attack of THF (solvent) was found to be the reason for the formation of impurity (8a). Execution of subsequent batches with proper controls arrested this impurity and successfully provided the Mirabegron with the desired quality.

Aryl or heteroaryl substituted pyrrolidine amide derivatives and application thereof

-

, (2019/05/22)

The invention discloses aryl or heteroaryl substituted pyrrolidine amide derivatives and an application thereof, in particular to a novel aryl or heteroaryl substituted pyrrolidine amide derivative and a pharmaceutical composition containing the same, which can be used for activating beta3-adrenergic receptor. The invention also relates to a method for preparing the compounds and pharmaceutical compositions, as well as an application thereof in preparing drugs for treating diseases or symptoms mediated by beta3-adrenergic receptor, and especially for treating the overactive bladder.

Acyl-substituted pyrrolidine amide derivative and application thereof

-

, (2019/06/12)

The invention discloses an acyl-substituted pyrrolidine amide derivative and application thereof. Specifically, the invention relates to a novel acyl-substituted pyrrolidine amide derivative and a pharmaceutical composition containing the compound, which can be used for activation of beta3-adrenoceptor. The invention also relates to a method for preparing the compound and the pharmaceutical composition and their application in the preparation of beta3-adrenoceptor activation-mediated diseases or symptoms, especially overactive bladder.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 223673-35-6